TABLE 1.
Background data for Alzheimer's disease cases and controls
| AD cases | Matched controls | P‐value | |
|---|---|---|---|
| N | 262 | 262 a | |
| Women, n (%) | 196 (74.8) | 196 (74.8) | |
| APOE ε4 carriers, n (%) | 128 (48.9) | 128 (48.9) | |
| HSV1 carriers, n (%) | 262 (100.0) | 262 (100.0) | |
| Age at inclusion, mean ± SD, (years) | 71.1 ± 8.8 | 70.8 ± 9.4 | .063 PST |
| Year of education, mean ± SD (years) | 7.8 ± 2.8 (N = 225) | 8.0 ± 3.0 (N = 225) | .467 PST |
| Cohort start year, median (range) | 1993 (1988–2003) | 1993 (1988–2003) | 1.000 WSRT |
| Follow‐up time, mean ± SD, (years) | 9.3 ± 6.1 | 13.5 ± 6.9 | <.001 PST |
| Antiviral drugb prescription during follow‐up, n (%) | 6 (2.3) | 20 (7.6) | 0.006 MN |
| Antiviral drug b prescribed/1000PY follow‐up, mean | 3.5 | 4.9 | .091 WSRT |
Abbreviations: AD, Alzheimer's disease; APOE ε4, allele 4 of the apolipoprotein E gene; HSV, herpes simplex virus type 1; MN, McNemar's test without Yates correction; PST, paired sample T‐test; PY, person‐year; SD, standard deviation; WSRT, Wilcoxon signed rank test.
a
224 unique individuals.
† Acyclovir analogue.